The report provides an in-depth analysis of reasons for the proliferation of contract research organizations as third-party service providers for biotechnology, pharmaceutical, and medical device companies.
It finds out the deal-making behavior and operational strategies of companies in the contract research organization (CRO) market in the past and trends that will shape the progression of this industry in the future. In this context, historically, deals that involved 40+ public and privately held CROs are evaluated for attributes of operational excellence.
This report presents a 360-degree overview of vital parameters that govern deals and operational moves in the CRO industry with the most remarkable business models employed for the same. In this report, each and every aspect pertaining to CRO deals and operational analysis is presented with real examples from the industry.
This includes type of deals and deal value, acquisitions and partnerships, and other ventures for CROs in the regions of North America, Asia Pacific, and Europe.
A CRO is an independent agency that steps in during the development process of new molecules. Typically, in the instance of a new molecule being identified by a pharma company, it is the CRO that performs clinical trials to examine the efficacy of the new molecule on humans.
As independent agencies, CROs provide an objective assessment of the efficacy of a new drug. Moreover, because CROs partner with many companies, they evaluate new molecules with a broader perspective than if the clinical trials were carried out by the pharma companies themselves.
For Sample Copy, click website
The analysis of the report is vitally important for a competitive understanding of the CRO industry. In this section of the report, both privately and publicly held CROs that top the list are mentioned and are profiled for competitive attributes. The companies thus profiled are EPS Corporation, Eurofins Scientific, Catalent, Charles River, PRA Health, Sanofi, Jubilant Biosys, Avillion, Celonic and PharmaLex, Noble Life Sciences, Cromos Pharma, Sun Pharma, ICON, Meiji Seika, Almac Group, INC Research, Hangzhou Tigermed, CMIC Holdings, Simbec Research, Laboratory Corporation of America Holdings, Consort Medical, Harlan Labs, Protagen, Recipharm, MPI Research, Pfizer, Quintiles, Parexel, Chiltern International, BioPharma, Carlina, Euprotech, Covance, WuXi PharmaTech, Novotech, Aurigon, and Assign.
This section also includes opportunities in the CRO industry that are expected to convert into acquisitions, licensing deals, and investment opportunities between top companies in this industry.
A distinguishing feature of the report is insights from industry opinion leaders such as the founder of WuXi Pharma Tech, the world’s largest CRO. Collating views of industry leaders, the report presents a factual understanding of how CROs are expected to display growth in the future years.
Trends and market size analytics of the development of CROs in the regional segments are presented by means of graphs and others statistical representations.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org